Research programme: anti-inflammatory therapeutics - Hutchison MediPharma

Drug Profile

Research programme: anti-inflammatory therapeutics - Hutchison MediPharma

Alternative Names: HMPL 507

Latest Information Update: 28 Sep 2015

Price : $50

At a glance

  • Originator Hutchison MediPharma
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 28 Aug 2015 Hutchison MediPharma plans a clinical trial for Inflammation
  • 19 Aug 2015 Janssen Pharmaceuticals terminates its licence for antiinflammatory candidates in China
  • 23 Dec 2008 Preclinical trials in Inflammation in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top